SCHEMBL5758920

SCHEMBL5758920

O=c1cc(C(F)(F)F)c2cc(Cc3ccc(S(=O)(=O)Nc4ccccc4CO)cc3)ccc2o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 2/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TLR9 Q9NR96 1/20 0.40
GAA P10253 2/20 0.39
PKM P14618 3/20 0.39
MCL1 Q07820 1/20 0.37
AR P10275 4/20 0.37
PGAM1 P18669 1/20 0.36
SLC16A3 O15427 1/20 0.36
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5860039 0.85 PKM (0.43) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL5761750 0.84 KDM4E (0.46) KMT2AMEN1KDM4EHPGDALDH1A1
SCHEMBL5762902 0.84 PKM (0.54) KMT2AMEN1ALDH1A1LMNAGAA
SCHEMBL5763908 0.83 IKBKB (0.49) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL5762510 0.82 NAMPT (0.44) KMT2AMEN1KDM4EHPGDALDH1A1
SCHEMBL5761962 0.82 KDM4E (0.46) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL5762853 0.81 L3MBTL1 (0.51) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL5860303 0.81 PKM (0.41) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL5762260 0.80 ACLY (0.41) KMT2AMEN1KDM4EHPGDALDH1A1
SCHEMBL5759756 0.80 LMNA (0.51) KMT2AMEN1KDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT KMT2A 816/4885MEN1 1982/4885KDM4E 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.